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A Novel Approach for Bisphosphonates: Ionic Liquids and
Organic Salts from Zoledronic Acid
Sjnia Teixeira+,[a, b] Miguel M. Santos+,[b] Ricardo Ferraz,[c, e] Cristina PrudÞncio,[c, f]
Maria H. Fernandes,[a, d] Jo¼o Costa-Rodrigues,[a, f, g] and Lu&s C. Branco*[b]
Novel ionic liquids and organic salts based on mono- or dia-
nionic zoledronate and protonated superbases, choline and n-
alkylmethylimidazolium cations, were prepared and character-
ized by spectroscopic and thermal analyses. Most of the pre-
pared salts display amorphous structures and very high solubil-
ity in water and saline solutions, especially the dianionic salts.
Among the zoledronate-based ionic compounds, those con-
taining choline [Ch] and methoxyethylmethylimidazolium
[C3OMIM] cations appear to have significant cytotoxicity
against human osteosarcoma cells (MG63) and low toxicity
toward healthy skin fibroblast cells. Because osteosarcoma is a
bone pathology characterized by an increase in bone turnover
rate, the results presented herein may be a promising starting
point for the development of new ionic pharmaceutical drugs
against osteosarcoma.
The discovery of novel effective drugs is currently one of the
greatest challenges for pharmaceutical industry.[1] The conven-
ient manipulation of solid active pharmaceutical ingredients
(APIs) has been associated with several drawbacks such as
polymorphic conversion, low bioavailability from crystalline
solids, and spontaneous crystallization of amorphous forms.[2–5]
In addition, it is recognized that the bioavailability of pharma-
ceutical drugs is significantly dependent on their water solubil-
ity as well as high permeability. In fact, many phase II trials of
new APIs fail because of their decreased bioavailability, a con-
sequence of poor solubility in water and biological fluids. The
most common approach followed by the pharmaceutical in-
dustry to increase the bioavailability of an API is to transform it
into a salt, usually by combining it with metallic cations such
as sodium or potassium, or with chloride anions, according to
the chemical structure of the API. Recently, the use of APIs as
organic salts and ionic liquids (API-OSILs) as an alternative has
been investigated by the academia.[6–9] The works involving
the preparation of API-OSILs from ampicillin, fluoroquinolones,
ibuprofen, ranitidine and lidocaine, and also acetylsalicylic and
salicylic acids, among others, have shown that the combination
of an API, either as a cation or as an anion, with suitable bio-
compatible counter-ions can increase the water solubility of
the parent drug and even change its biological effect.[10–21] In
face of these results, it is suggested that the oral bioavailability
of the formed API-OSILs is particularly enhanced, or alternative-
ly it may open new perspectives for their local administration/
application. Therefore, the therapeutic dosage of the drug may
be reduced, decreasing side effects.
Bisphosphonates (BPs) are considered the primary therapy
for skeletal disorders due to their high affinity for bone tissue.
BPs are stable analogues of the inorganic pyrophosphate, an
endogenous regulator of bone mineralization, which can with-
stand hydrolysis in the gastrointestinal tract.[22–24] Their confor-
mation allows targeting the bone because of their three-di-
mensional structure, which makes them primary agents against
osteoclast-mediated bone loss. In addition, recently they have
also been considered as potential antitumor agents due to
their ability to induce tumor cell apoptosis, inhibition of cell
adhesion, invasion and proliferation, modulation of the
immune system to target and eliminate cancer cells as well as
affect the angiogenic mechanisms. However, zoledronic acid,
one of the most effective BPs, lacks absorption in the GI tract
and is only administered intravenously. In addition, many debil-
itating side effects are described such as muscle, joint and
bone pain, muscle spasms, numbness, among many others. In
this context, there is a need to develop new ways to increase
oral bioavailability of zoledronic acid, while the side effects are
significantly reduced.
Potential formulations of zoledronic acid and other bi-
sphosphonates for oral administration have been reported re-
cently by pharmaceutical companies.[25–27] Such formulations
comprise, among other possibilities, the use of BPs as organic
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salts, in particular quaternary ammonium salts. However, no
data on the synthesis, bioavailability and/or toxicity of such
salts are presented.
Thus, in this line of thought we report the preparation of
twelve OSILs from zoledronic acid (Zol-OSILs) in quantitative
yields by following two distinct sustainable and straightfor-
ward methodologies, according to the type of cation. All pre-
pared Zol-OSILs were characterized by spectroscopic and ther-
mal analysis and their solubility in water and biological fluids
was determined. An evaluation of the toxicity toward human
skin fibroblasts and human lung and bone (osteosarcoma)
cancer cells was performed. The zoledronic acid-based OSILs
were prepared using the cations depicted in Figure 1, which
were selected due to their low cytotoxicity.[20, 21, 28]
Protic zoledronate-OSILs were prepared by adding 1 or
2 equivalents of organic superbases, more specifically 1,1,3,3-
tetramethylguanidine (TMG) and 1,5-diazabicyclo(4.3.0)non-5-
ene (DBN), to a solution of zoledronic acid, whose phospho-
nate group(s) become(s) deprotonated (general procedure A in
Scheme 1).[15]
With this straightforward synthetic methodology two mono-
anionic and two dianionic zoledronic acid-based ionic salts
were prepared. Room temperature ionic liquids (RTILs) were
obtained whenever two units of superbase were added, while
the monoionic compounds were obtained as protic organic
solid salts.
For the deprotonation of zoledronic acid with cholinium and
methylimidazolium salts, a different methodology was em-
ployed (general procedure B from Scheme 1), based on previ-
ous reports from our group on the preparation of other API-
OSILs.[17, 20] Briefly, the cations in the form of hydroxide salts are
firstly prepared from the corresponding chloride or bromide
salts by reaction with hydroxide exchange resins (e.g. , Amber-
lyst A26-OH) in methanolic solution. The very basic solutions
are then neutralized by addition to an aqueous solution of zo-
ledronic acid yielding the desired Zol-OSILs in quantitative
yields. By using one or two molar equivalents of cation salts
we synthesized four monoionic organic salts and four dianionic
Zol-based RTILs.
All products were characterized by NMR (1H and 13C) and
FTIR spectroscopies, as well as elemental analysis. The thermal
properties were evaluated by DSC and the solubility in water
and saline solution was determined for all compounds. Addi-
tionally, the structure of [DBNH][Zol] was definitively estab-
lished by single crystal X-ray diffraction analysis. This salt crys-
tallized from an asymmetric unit composed of one zwitterionic
Zol unit where both phosphonate groups are deprotonated
and one nitrogen atom of the imidazolium moiety is protonat-
ed. The DBN unit is protonated at the nitrogen atom from the
6-membered ring (Figure 2). The crystal structure is stabilized
by several intra and intermolecular hydrogen bonds (see pack-
ing in Figures S49 and S50 in the Supporting Information).
All prepared Zol-OSILs were studied by DSC and the melting,
crystallization and glass transition temperatures were deter-
mined (see Table 1) and compared with the data from the
parent drug. Depending on the hydration level, zoledronic acid
displays a melting point between 214 and 230 8C, to which de-
composition rapidly follows.[29] Only two of the prepared Zol-
OSILs, have a melting point in the same range, namely [TMGH]
[Zol] (225.3 8C) and [Ch][Zol] (220.4 8C). These two compounds,
in addition to the remaining four solid compounds obtained,
are not considered ionic liquids, but organic salts because their
melting temperatures are higher than 100 8C.
[C3OMIM][Zol] shows a first melt at 125.9 8C followed by a
cold crystallization step at 139.8 8C, to which then follows a
second melt that occurs at 185.0 8C. After this the compound
remains in an amorphous state characterized by a glass transi-
tion temperature of 45.7 8C. [EMIM][Zol] also becomes amor-
phous after first melt (at 198.0 8C) with a glass transition tem-
perature of 29.5 8C.
Figure 1. Structures of mono- and dianionic zoledronic acid, protonated su-
perbases and organic cations.
Scheme 1. Synthetic methodologies A and B for the synthesis of Zol-OSILs.
Figure 2. ORTEP-3 diagram of [DBNH][Zol] with thermal ellipsoids drawn at
30 % probability level illustrating one cationic DBN unit and one zwitterionic
Zol entity bearing two anionic phosphonate groups and one cationic imida-
zolium moiety. The hydrogen, carbon, oxygen, nitrogen and phosphorous
atoms are shown in white, grey, red, blue, and orange, respectively.
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Even though [Ch]2[Zol] is a thick white paste at room tem-
perature, it was possible to determine its melting temperature
and the corresponding crystallization peak by DSC, which
occur at 18.6 (exo) and 13.2 8C (endo), respectively. Except for
this ionic liquid, all remaining Zol-RTILs are clearly amorphous
compounds with defined glass transition temperatures.
As expected, all ionic liquids and salts were more soluble in
water and saline solution at 37 8C than neutral zoledronic acid.
Figure 3 summarizes the data obtained from the solubility
studies. All dianionic zoledronate ionic liquids were more solu-
ble in the tested media than the monoanionic siblings, with
three of them ([TMGH]2[Zol] , [DBNH]2[Zol] and [C3OMIM]2[Zol])
being completely soluble in water and saline solution. For un-
known reasons, [EMIM]2[Zol] was the only ionic compound
which was less soluble in water than in saline solution (in
which, in fact, it was entirely soluble). Moreover, the monoionic
salts were found to be between 214 and 624-fold more soluble
in water than the neutral parent drug. With the exception of
[C2OHMIM][Zol] , the monoionic compounds had solubility in
saline solution lower than 25 mg mL@1 with a ratio between 1.5
and 7.0 times in comparison with zoledronic acid.
The cytotoxicity (IC50) data of the studies with the prepared
zoledronic-containing ILs in different human cell lines and fi-
broblasts are presented in Table 2. In the tested concentration
range, the activity of zoledronic acid toward normal and osteo-
sarcoma cells only differed in one order of magnitude, while
no activity was observed for breast cancer cells. The combina-
tion of the drug with [TMGH] yielded an inactive compound
toward all types of cells tested. In general, all monoanionic
salts present lower toxicity to skin fibroblasts than the dianion-
ic ionic liquids, with the rare exception of those with [EMIM]
cation. More specifically, the salts containing [TMGH], [DBNH],
[EMIM]2 and [C3OMIM] were found to be the least toxic from
the tested set toward the non-neoplastic cells, with IC50
+2.5 mm. These IC50 values are at least three orders of magni-
tude lower than the one found for Zol (2.43 mm). Regarding
the effects on breast cancer cells (T47D), all tested salts, with
the exception of [TMGH][Zol] , showed cytotoxic activity where-
as Zol was inactive. However, the profile was similar to the one
found with skin fibroblasts, which means that they are not se-
lective for any of these cells. In the case of the human osteo-
sarcoma cell line MG63, [Ch][Zol] and [C3OMIM]2[Zol] showed
IC50 values of 0.15 and 0.33 nm, respectively, which are three
orders of magnitude lower than for zoledronic acid (57 mm).
The selectivity ratio of [Ch][Zol] between normal and MG63
cells was found to be extremely high, in the order of 104, simi-
lar to the one found for [EMIM]2[Zol] , although its activity
toward osteosarcoma cell line was lower (IC50 = 0.5 mm). Finally,
[DBNH][Zol] and [EMIM]2[Zol] also display very high selectivity
ratios as they display very low toxicity toward fibroblasts.
The data retrieved from this study may be particularly rele-
vant, as osteosarcoma cells are known to induce disturbances
Table 1. Physical state, melting, crystallization and glass transition tem-
peratures of the prepared Zol-OSILs.
Salt Physical state Tm [8C] Tc [8C] Tg [8C]
[TMGH][Zol] White solid 225.3 – –
[TMGH]2[Zol] Colorless paste – – 12.4
[DBNH][Zol] White solid 208.7 – 45.7
[DBNH]2[Zol] Colorless paste – – 15.1
[Ch][Zol] White solid 220.4 – 78.4
[Ch]2[Zol] White paste 18.6 13.2 –
[EMIM][Zol] White solid 198.0 – 29.5
[EMIM]2[Zol] Colorless paste – – 31.7
[C2OHMIM][Zol] White solid 143.8;
195.9
170.1[a] 57.3
[C2OHMIM]2[Zol] Colorless paste – – 10.8
[C3OMIM][Zol] White solid 125.9;
185.0
139.8[a] 45.7
[C3OMIM]2[Zol] Colorless paste – – 3.4
[a] Cold crystallization.
Figure 3. Solubility in water and saline solution at 37 8C of zoledronic acid
and Zol-OSILs (detection limit is 5 g mL@1, represented by the upper thresh-
old).
Table 2. Cytotoxicity of Zol-OSILs on human skin fibroblasts (SF) and
human breast cancer (T47D) and osteosarcoma (MG63) cell lines.
Compound IC50 [mm] IC50(SF)/
IC50(MG63)
SF T47D MG63
Zol 2.43 V 10-@13 ND[a] 5.74 V 10@4 4.2
[TMGH][Zol] ND[a] ND[a] ND[a] –
[TMGH]2[Zol] 1.02 V 10
@3 6.87 V 10@3 6.97 1.5 V 10@4
[DBNH][Zol] 2.50 1.98 V 10-@1 1.65 V 10@3 1.5 V 103
[DBNH]2[Zol] 5.96 V 10
@7 1.25 V 10@7 ND[a] –
[Ch][Zol] 3.98 V 10@3 6.15 V 10@4 1.51 V 10@7 2.6 V 104
[Ch]2[Zol] 1.46 V 10
@7 1.69 V 10@6 2.10 V 10@2 7.0 V 10@6
[EMIM][Zol] 4.97 V 10@2 2.11 V 10@3 ND[a] –
[EMIM]2[Zol] 17.8 3.82 V 10
@2 5.01 V 10@4 3.6 V 104
[C2OHMIM][Zol] ND
[a] 1.84 V 10@2 5.60 V 10@4 –
[C2OHMIM]2[Zol] 1.58 V 10
@7 1.48 V 10@7 5.58 V 10@5 2.8 V 10@3
[C3OMIM][Zol] 14.7 2.01 12.3 1.2
[C3OMIM]2[Zol] 9.71 V 10
@5 8.02 V 10@3 3.27 V 10@7 3.0 V 102
[a] Not detected in the tested concentration range.
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in bone metabolism, with an increase in bone turnover
rate.[30–32] Thus, the synthesis of compounds with a simultane-
ous potential inhibitory effect on bone resorption and a selec-
tive cytotoxicity against osteosarcoma cells may represent an
important strategy for the development of new drugs against
osteosarcoma.
Experimental Section
General procedure (A) for the synthesis of Zol-OSILs with organ-
ic superbases as cations : To a dispersion of zoledronic acid
(500 mg, 1.84 mmol) in MeOH/H2O (15 mL, 1:1) a methanolic solu-
tion of 1 or 2 molar equivalents of organic superbase (15 mg mL@1)
was added dropwise under magnetic stirring. After reacting for 1 h
the solvent was evaporated and the desired product was dried
under vacuo for 24 h.
General procedure (B) for the preparation of Zol-OSILs with am-
monium cations : The halide salts of the selected quaternary am-
monium cations were dissolved in methanol and passed slowly
through an anion-exchange column A-26(OH) (3 equivalents). The
freshly formed methanolic solutions of the corresponding hydrox-
ide salts (1 or 2 equivalents) were consequently added dropwise to
zoledronic acid (500 mg, 1 equivalent) dispersed in H2O under
magnetic stirring. After 1 h, the solvent of the clear solution was
evaporated and the desired product was dried under vacuo for
24 h.
The detailed experimental procedures of the solubility and cytotox-
icity studies are described in the Supporting Information.
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